HRT
Herantis Pharma
Stock
Stock
ISIN: FI4000087861
Ticker: HRTIS
FI4000087861
HRTIS
Price
Price
CHART BY
Frequently asked questions
What is Herantis Pharma's market capitalization?
The market capitalization of Herantis Pharma is 52.29M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Herantis Pharma?
Herantis Pharma's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.25. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Herantis Pharma's stock?
Currently, 1 analysts cover Herantis Pharma's stock, with a consensus target price of 2.50. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Herantis Pharma?
Herantis Pharma's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -5.23M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Herantis Pharma?
Herantis Pharma has a free cash flow of -6.90M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Herantis Pharma have, and what sector and industry does it belong to?
Herantis Pharma employs approximately 11 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Herantis Pharma's shares?
The free float of Herantis Pharma is 18.22M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- 52.29M
- EPS (TTM)
- -$0.25
- Free Float
- 18.22M
- EBITDA (TTM)
- -5.23M
- Free Cashflow (TTM)
- -6.90M
Pricing
- 1D span
- $2.479$2.554
- 52W span
- $1.309$4.501
Analyst Ratings
The price target is 2.50 and the stock is covered by 1 analysts.
Buy
0
Hold
0
Sell
1
Information
Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. It offers medicinal products such as Cis-UCA eye drops for dry eye, CDNF for Parkinson's disease, Lymfactin for secondary lymphedema, Cis-UCA emulsion cream for atopic dermatitis, and CDNF for amyotrophic lateral sclerosis (ALS). The company was founded by Eero Hemminki Castren, Henri Juhani Huttunen, Heikki Rauvala, and Mart Saarma in 2008 and is headquartered in Espoo, Finland.
- Employees
- 11
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- FI4000087861
- Primary Ticker
- HRTIS
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet